

GenScript ProBio partners with DAAN Bio Therapeutics for novel drug discovery

14 July 2022 | News

GenScript ProBio and DAAN have agreed to strengthen their cooperation in the cell and gene therapy (CGT) and biologics field through this MOU

GenScript ProBio, a global CDMO, and South Korea-based startup DAAN Bio Therapeutics, have entered into a strategic cooperation concerning the development for innovation drug discovery & development.

Through this agreement, both companies will strategically cooperate in the overall development process, such as discovery, manufacturing, and clinical trials of antibody and cell treatments, and related research and service projects.

DAAN Bio Therapeutics has conducted single cell transcriptomic and proteomic biomarker analysis through its own analysis platform using tissues secured from solid cancer patients along with DAAN Cancer Research Institute and Yonsei New Il Han Institute for Integrative Cancer Research.

Accordingly, DAAN Bio Therapeutics signed a contract manufacturing organization (CMO) service through GenScript ProBio to develop antibodies that specifically bind to the discovered target material, and established its own bispecific antibody production pipeline using antibodies derived through GMP production.